Mammoth Biosciences, a CRISPR startup spun out of UC Berkeley, took a unique approach, initially focusing only on diagnostics, and employing the DNA and RNA-cutting proteins Cas12 and Cas13 instead of the better-known Cas9. With a recent $45 million Series B round, Mammoth is doubling down on diagnostics while also expanding into gene editing and therapeutics with additional novel enzymes they have developed like the nano-sized Cas14.
Speaker: Trevor Martin, Mammoth Biosciences
Contact:Website: Click to Visit
Save this Event:iCalendar
Windows Live Calendar